Page 5 - Slrn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Slrn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Slrn Today - Breaking & Trending Today

Acelyrin (NASDAQ:SLRN) PT Lowered to $13.00 at Morgan Stanley

Acelyrin (NASDAQ:SLRN – Free Report) had its price objective reduced by Morgan Stanley from $19.00 to $13.00 in a research note published on Wednesday morning, Benzinga reports. They currently have an equal weight rating on the stock. Several other analysts also recently weighed in on SLRN. Jefferies Financial Group reduced their price objective on shares […] ....

New York , United States , Hidradenitis Suppurativa , Morgan Stanley , Jefferies Financial Group , Acelyrin Company Profile , Acelyrin Inc , York State Common Retirement Fund , Osaic Holdings Inc , Tower Research Capital , Free Report , Financial Group , Moderate Buy , Get Free Report , Research Capital , New York State Common Retirement Fund , Psoriatic Arthritis , Acelyrin Daily , Nasdaq Slrn , Lower Price Target ,

Acelyrin's (SLRN) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Acelyrin (NASDAQ:SLRN – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a $30.00 price objective on the stock. Separately, Morgan Stanley lowered Acelyrin from an overweight rating to an equal weight rating and lowered their price […] ....

Hidradenitis Suppurativa , Jpmorgan Chase Co , Bio Partners , Ayurmaya Capital Management Company , Acelyrin Inc , Morgan Stanley , Free Report , Moderate Buy , Get Free Report , Maya Capital Management Company , Psoriatic Arthritis , Acelyrin Daily , Nasdaq Slrn , Reiterated Rating , Hc Wainwright ,

Acelyrin (NASDAQ:SLRN) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Acelyrin (NASDAQ:SLRN – Free Report) in a research note issued to investors on Tuesday, Benzinga reports. HC Wainwright currently has a $30.00 price target on the stock. Separately, Morgan Stanley cut Acelyrin from an overweight rating to an equal weight rating and dropped their target price […] ....

Hidradenitis Suppurativa , Jennison Associates , Td Asset Management Inc , Morgan Stanley , Acelyrin Company Profile , York Mellon Corp , Acelyrin Inc , Free Report , Moderate Buy , Trading Down , Get Free Report , Capital Management , Montreal Can , New York Mellon Corp , Management Inc , Psoriatic Arthritis , Acelyrin Daily , Nasdaq Slrn , Reiterated Rating , Hc Wainwright ,